Learn more Got it! What if it's possible to revolutionize d Shaping new possibilities for patients everywhere Zymeworks is a clinical-stage biotechnology company united in creating disruptive therapeutic platforms and impactful biotherapeutics that return patients to their loved ones, disease free. FOR PATIENTS NEWS Nov 19, 2021 Zymeworks Announces Abstract For Zanidatamab In Late-Line HER2-Positive Breast Cancer At The San Antonio Breast Cancer Symposium (SABCS) Nov 17, 2021 Mediacorp Recognizes Zymeworks as One of Canada’s 2022 Top 100 Employers news Nov 09, 2021 Zymeworks Launches Global Phase 3 Zanidatamab Trial In First-Line HER2‑Positive Gastroesophageal Adenocarcinoma (GEA) science Nov 03, 2021 Zymeworks-GSK Collaboration Leads To Design and Validation of a Novel Engineered, FcγRIIb-Selective Fc Platform for Therapeutic Antibody Development SEE ALL NEWS PIPELINE OF POTENTIAL LEAD PRODUCT CANDIDATES Zanidatamab HER2 x HER2 Bispecific Antibody PIVOTAL FULL DETAILS ZW49 HER2 x HER2 Bispecific Antibody Drug Conjugate (ADC) PHASE 1 FULL DETAILS PRECLINICAL & ADVANCED DISCOVERY Antibody Drug Conjugate (ADC) PRECLINICAL FULL DETAILS T Cell Engaging Bispecifics PRECLINICAL FULL DETAILS Microenvironment Modulators PRECLINICAL FULL DETAILS Cytokine Receptor Modulators PRECLINICAL FULL DETAILS EXPLORE CANDIDATES Four platforms. Endless possibilities. Powerful, versatile protein engineering platforms for highly customized therapeutics including cytotoxic anti-tumor biologics, antibody drug conjugates, and immuno-oncology therapies. EXPLORE PLATFORMS AZYMETRIC™ Build the Best Bispecifics by creating tailored multifunctional therapeutics that enable enhanced efficacy and new biological approaches for treating diseases ZYMELINK™ Enhance Therapeutic Response with a modular suite of proprietary cytotoxins (cell-killing compounds), stable linkers, and conjugation technologies. EFECT™ Customize & Optimize Immune Response using precise antibody Fc modifications that tailor the antibody-mediated immune response PROTECT™ Tumor‑Specific Immune Co‑stimulation in a single, transferable, conditionally active design one Zymeworks. Zymeworks employees innovate, act with integrity, collaborate, embrace diversity & care JOIN ZYMEWORKS TECHNOLOGY Azymetric™ ZymeLink™ EFECT™ ProTECT™ Science PIPELINE Zanidatamab ZW49 Preclinical Candidates Partnerships Publications For Patients INVESTORS Stock Info News Releases Events & Presentations Financials Governance CORPORATE Leadership Board of Directors Careers Legal Privacy Contact Twitter LinkedIn